ArticleCancer management and research2020
MRI-Based Radiomic Signature as a Prognostic Biomarker for HER2-Positive Invasive Breast Cancer Treated with NAC.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive value of radiomics-based machine learning for the disease-free survival in breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Ultrasound-based multiregional radiomics nomogram for predicting recurrence in HER2-positive breast cancer.BMC medical imaging · 2026Article
- Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria.La Radiologia medica · 2025Article
- MRI-based artificial intelligence models for post-neoadjuvant surgery personalization in breast cancer: a narrative review of evidence from Western Pacific.The Lancet regional health. Western Pacific · 2025Review
- Article
- The clinical validity of radiomics-based prediction of molecular subtypes in breast cancer from digital mammary tomosynthesis.Frontiers in oncology · 2025Article
- Review
- The use of radiomics in magnetic resonance imaging for the pre-treatment characterisation of breast cancers: A scoping review.Journal of medical radiation sciences · 2023Article
- Radiomic signatures based on pretreatment 18F-FDG PET/CT, combined with clinicopathological characteristics, as early prognostic biomarkers among patients with invasive breast cancer.Frontiers in oncology · 2023Article
- Artificial intelligence in breast cancer imaging: risk stratification, lesion detection and classification, treatment planning and prognosis-a narrative review.Exploration of targeted anti-tumor therapy · 2022Review
- An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer.Journal of clinical medicine · 2021Article
- A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy.Frontiers in genetics · 2021Article
- Integrative Analysis of Histopathological Images and Genomic Data in Colon Adenocarcinoma.Frontiers in oncology · 2021Article
- Value of Machine Learning with Multiphases CE-MRI Radiomics for Early Prediction of Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Invasive Breast Cancer.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify MRI-based radiomics signature (Rad-score) as a biomarker of risk stratification for disease-free survival (DFS) in patients with HER2-positive invasive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy (NAC) and establish a radiomics-clinicoradiologic-based nomogram that combines Rad-score, MRI findings, and clinicopathological variables for DFS estimation. PATIENTS AND
methodsA total of 127 patients were divided into a training set and testing set according to the ratio of 7:3. Radiomic features were extracted from multiphase CE-MRI (CE
resultsThe Rad-score stratified patients into high- and low-risk groups for DFS in the training set (
conclusionThe Rad-score is an independent biomarker for the estimation of DFS in invasive HER2-positive breast cancer with NAC and the radiomics-clinicoradiologic-based nomogram improved individualized DFS estimation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.